Assertio Therapeutics Net Worth
Assertio Therapeutics Net Worth Breakdown | ASRT |
Assertio Therapeutics Net Worth Analysis
Assertio Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Assertio Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Assertio Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Assertio Therapeutics' net worth analysis. One common approach is to calculate Assertio Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Assertio Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Assertio Therapeutics' net worth. This approach calculates the present value of Assertio Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Assertio Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Assertio Therapeutics' net worth. This involves comparing Assertio Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Assertio Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Assertio Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Assertio Therapeutics' net worth research are outlined below:
| Assertio Therapeutics generated a negative expected return over the last 90 days | |
| Assertio Therapeutics has some characteristics of a very speculative penny stock | |
| Assertio Therapeutics has high historical volatility and very poor performance | |
| Assertio Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 152.07 M. Net Loss for the year was (331.94 M) with profit before overhead, payroll, taxes, and interest of 138.29 M. | |
| Latest headline from thelincolnianonline.com: Assertio Holdings, Inc. Director Heather L. Mason Buys 75,000 Shares |
Assertio Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Assertio Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Assertio Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Assertio Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Assertio Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Assertio Therapeutics backward and forwards among themselves. Assertio Therapeutics' institutional investor refers to the entity that pools money to purchase Assertio Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Investments Llc | 2024-09-30 | 876 K | Amvescap Plc. | 2024-06-30 | 564.1 K | Bridgeway Capital Management, Llc | 2024-09-30 | 498.6 K | Susquehanna International Group, Llp | 2024-06-30 | 490.3 K | Empowered Funds, Llc | 2024-06-30 | 409.9 K | Jane Street Group Llc | 2024-06-30 | 406.6 K | Perritt Capital Management Inc. | 2024-09-30 | 390.1 K | Bank Of New York Mellon Corp | 2024-06-30 | 351.7 K | State Street Corp | 2024-06-30 | 339.3 K | Nantahala Capital Management, Llc | 2024-09-30 | 8.9 M | Vanguard Group Inc | 2024-09-30 | 4.5 M |
Follow Assertio Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 81.8 M.Market Cap |
|
Project Assertio Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.90) | (1.80) | |
| Return On Capital Employed | (1.26) | (1.20) | |
| Return On Assets | (1.16) | (1.10) | |
| Return On Equity | (2.41) | (2.29) |
When accessing Assertio Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Assertio Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Assertio Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Assertio Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Assertio Therapeutics. Check Assertio Therapeutics' Beneish M Score to see the likelihood of Assertio Therapeutics' management manipulating its earnings.
Evaluate Assertio Therapeutics' management efficiency
Assertio Therapeutics has return on total asset (ROA) of (0.0144) % which means that it has lost $0.0144 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4236) %, meaning that it created substantial loss on money invested by shareholders. Assertio Therapeutics' management efficiency ratios could be used to measure how well Assertio Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -1.8 in 2024. Return On Capital Employed is likely to gain to -1.2 in 2024. Liabilities And Stockholders Equity is likely to gain to about 336.5 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 72.3 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.94 | 1.85 | |
| Tangible Book Value Per Share | 0.38 | 0.39 | |
| Enterprise Value Over EBITDA | (0.20) | (0.19) | |
| Price Book Value Ratio | 0.55 | 0.52 | |
| Enterprise Value Multiple | (0.20) | (0.19) | |
| Price Fair Value | 0.55 | 0.52 | |
| Enterprise Value | 1.5 B | 1.6 B |
The strategic initiatives led by Assertio Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 0.3536 | Revenue 125.8 M | Quarterly Revenue Growth (0.18) | Revenue Per Share 1.322 | Return On Equity (0.42) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Assertio Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Assertio Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Assertio Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Assertio Therapeutics time-series forecasting models is one of many Assertio Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Assertio Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Assertio Therapeutics Earnings per Share Projection vs Actual
Assertio Therapeutics Corporate Management
| Jack Hoblitzell | VP Operations | Profile | |
| MD MBA | Senior Medical | Profile | |
| Ajay Patel | VP Officer | Profile | |
| Sam Schlessinger | Senior Counsel | Profile | |
| Molly Dir | Senior Administration | Profile | |
| Bill Iskos | Senior Operations | Profile |
Already Invested in Assertio Therapeutics?
The danger of trading Assertio Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Assertio Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Assertio Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Assertio Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Assertio Stock Analysis
When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.